TCV Trust & Wealth Management Inc. Has $18.19 Million Position in Eli Lilly and Company $LLY

Key Points

• TCV Trust & Wealth Management Inc. reduced its stake in Eli Lilly and Company by 2.8%, selling 682 shares, now holding 23,335 shares valued at approximately $18.19 million.
• Eli Lilly reported a quarterly EPS of $6.31, exceeding expectations and showcasing a revenue increase of 37.6% year-over-year to $15.56 billion.
• The company declared a quarterly dividend of $1.50, representing a 0.8% yield, with a payout ratio of 39.22%.

TCV Trust & Wealth Management Inc. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,335 shares of the company's stock after selling 682 shares during the quarter. Eli Lilly and Company comprises about 1.6% of TCV Trust & Wealth Management Inc.'s investment portfolio, making the stock its 15th biggest position. TCV Trust & Wealth Management Inc.'s holdings in Eli Lilly and Company were worth $18,190,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Hobbs Wealth Management LLC lifted its stake in shares of Eli Lilly and Company by 0.8% during the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after purchasing an additional 12 shares during the period. Hixon Zuercher LLC grew its stake in shares of Eli Lilly and Company by 0.7% in the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after buying an additional 12 shares in the last quarter. O Brien Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after buying an additional 12 shares in the last quarter. Ascent Capital Management LLC grew its stake in shares of Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after buying an additional 12 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners increased its position in shares of Eli Lilly and Company by 2.7% during the first quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock worth $407,000 after acquiring an additional 13 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Berenberg Bank reaffirmed a "hold" rating and set a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday. JPMorgan Chase & Co. decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday. UBS Group decreased their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Leerink Partners restated a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, Morgan Stanley restated an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $939.61.

Insider Activity

In other news, Director J Erik Fyrwald bought 1,565 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock valued at $2,894,841 over the last 90 days. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY traded down $9.41 during mid-day trading on Friday, reaching $753.52. 7,319,147 shares of the company's stock traded hands, compared to its average volume of 3,181,974. The business's 50-day moving average price is $738.37 and its 200-day moving average price is $770.79. The stock has a market capitalization of $713.18 billion, a P/E ratio of 49.25, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $939.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the company earned $3.92 earnings per share. The firm's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were issued a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's payout ratio is presently 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.